The Outcomes of Myeloid Sarcoma in 64 Pediatric Patients and the Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Treatment Results
Authors:
- Magdalena SamborskaMSMagdalena Samborska
- Jolanta Skalska-SadowskaJSJolanta Skalska-Sadowska
- Jacek WachowiakJWJacek Wachowiak
- Małgorzata CzogałaMCMałgorzata Czogała
- Walentyna BalwierzWBWalentyna Balwierz
- Szymon SkoczenSSSzymon Skoczen
- Natalia BartoszewiczNBNatalia Bartoszewicz
- Jan StyczynskiJSJan Styczynski
- Tomasz OciepaTOTomasz Ociepa
- Tomasz UrasińskiTUTomasz Urasiński
- Grażyna WróbelGWGrażyna Wróbel
- Krzysztof KalwakKKKrzysztof Kalwak
Preprint
- 9 February 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Myeloid sarcoma (MS) is a malignant extramedullary tumor that occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). The standard first-line treatment for MS is intensive chemotherapy according the AML protocol, regardless of bone marrow involvement. The role of allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of pediatric patients with MS requires further investigation. The aim of the study was to evaluate treatment outcomes for MS in pediatric patients with a focus on assessing the impact of allogeneic hematopoietic stem cell transplantation (alloHSCT) on treatment efficacy. The study included 64 patients aged 0 to 19 years from 15 pediatric oncology centers in Poland, who were diagnosed with MS between 1998 and 2024. The probability of 5-year overall survival (pOS) for the entire cohort was 0.63 ± 0.07, while the 5-year event-free survival (pEFS) and 5-year relapse-free survival (pRFS) were 0.62 ± 0.07 and 0.72 ± 0.07, respectively. Treatment outcomes were compared between patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) in first complete remission (ICR) (n1 = 17/64; 27%) and those who did not receive alloHSCT (n2 = 47/64; 73%). In the alloHSCT group (n1), the estimated survival probabilities were pOS = 0.49 ± 0.13, pEFS = 0.44 ± 0.14, and pRFS = 0.40 ± 0.14. In the non-alloHSCT group (n2), these values were pOS = 0.68 ± 0.08, pEFS = 0.68 ± 0.08, and pRFS = 0.84 ± 0.06. The difference in pRFS between groups n1 and n2 was statistically significant (p = 0.0049). Extramedullary relapse was more frequently observed in patients who had undergone allogeneic hematopoietic stem cell transplantation (alloHSCT) (p = 0.0001). Further research is needed to identify effective strategies for sustaining remission in patients with MS after alloHSCT.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Real-world experience with venetoclax-based therapy for patients with myeloid sarcomaDiscover Oncology, 2024
- Extramedullary infiltration in pediatric acute myeloid leukemia: Results from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiativePediatric Blood & Cancer, 2024
- Myeloid sarcoma: more and less than a distinct entityAnnals of Hematology, 2023
- Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutationsCancer, 2022
- Characteristics and transplant outcome of myeloid sarcoma: a single-institute studyInternational Journal of Hematology, 2021
- An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 InhibitorJAMA Ophthalmology, 2020
- Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantationInternational Journal of Hematology, 2020
- Myeloid sarcoma is associated with poor clinical outcome in pediatric patients with acute myeloid leukemiaJournal of Cancer Research and Clinical Oncology, 2020
- Extramedullary leukemia in children with acute myeloid leukemia: A population‐based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO)Pediatric Blood & Cancer, 2017
- Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2011